Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer – Yahoo Finance

Related Articles:

• Monthly Research Review – September 2019 September 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during September 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer - GlobeNewswire January 4, 2021 Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer  GlobeNewswire
• Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer - BioSpace January 4, 2021 Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer  BioSpace
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• MODAG Appoints Dr. Johannes Levin as Chief Medical Officer - Yahoo Finance September 4, 2019 MODAG Appoints Dr. Johannes Levin as Chief Medical Officer  Yahoo FinanceMODAG today announced the appointment of Johannes Levin, M.D., as Chief Medical Officer (CMO). Dr. Levin brings with him over ten years of experience in ...
• Axovant Appoints David Nassif as Chief Financial Officer and Expands Board of Directors - Yahoo Finance July 1, 2019 Axovant Appoints David Nassif as Chief Financial Officer and Expands Board of Directors  Yahoo FinanceAxovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced the appointment of David Nassif as ...
• Annovis Appoints Jeffrey McGroarty Chief Financial Officer - Yahoo Finance July 9, 2019 Annovis Appoints Jeffrey McGroarty Chief Financial Officer  Yahoo FinanceAnnovis Bio, Inc., a biopharmaceutical company developing novel therapies for the treatment of Alzheimer's, Parkinson's and other neurodegenerative diseases, ...
• Yumanity Therapeutics Appoints Richard Peters, M.D., Ph.D., as Chief Executive Officer - Yahoo Finance July 10, 2019 Yumanity Therapeutics Appoints Richard Peters, M.D., Ph.D., as Chief Executive Officer  Yahoo FinanceYumanity Therapeutics, a company focused on discovering and developing transformative therapies to treat neurodegenerative diseases, today announced the ...
• PsychoGenics Appoints Mark A. Varney, Ph.D. as Chief Scientific Officer - Yahoo Finance November 4, 2019 PsychoGenics Appoints Mark A. Varney, Ph.D. as Chief Scientific Officer  Yahoo Finance
• Yumanity Therapeutics Appoints Neuroscience Veteran, Brigitte Robertson, M.D., as Chief Medical Officer - Yahoo Finance November 18, 2019 Yumanity Therapeutics Appoints Neuroscience Veteran, Brigitte Robertson, M.D., as Chief Medical Officer  Yahoo Finance
• MODAG Appoints Dr. Johannes Levin as Chief Medical Officer - BioSpace September 4, 2019 MODAG Appoints Dr. Johannes Levin as Chief Medical Officer  BioSpaceWENDELSHEIM, Germany--(BUSINESS WIRE)-- MODAG today announced the appointment of Johannes Levin, M.D., as Chief Medical Officer (CMO). Dr. Levin ...
• Monthly Research Review: Jaunary 2020 January 31, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2020. The post is divided into seven parts based on the type of research: Basic biology, Disease mechanism, Clinical research, New clinical trials, Clinical trial news, Other news, and…
• GB Sciences Granted US Patent for Cannabinoid-based Formulations for Parkinson’s May 7, 2020 GB Sciences has been granted a patent from the U.S. Patent and Trademark Office (USPTO) covering the use of its proprietary cannabinoid-containing complex mixtures for treating Parkinson’s disease, the company announced. GB Sciences is creating a pipeline of new medicines based on cannabinoids, the pharmacologically active compounds that give the cannabis plant its medical and recreational properties. The patent — number 10,653,640…
• James Parkinson’s Work Paved the Way for Future Research October 2, 2019 James Parkinson changed the course of medical history when he first described the “Shaking Palsy” in 1817, at a time when little was known about neurological and degenerative diseases. I decided to delve into the history of the disease to see how it might relate to modern medical practices. I wondered how James Parkinson’s research made current treatments possible for…
• 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
• ProMIS Neurosciences Develops Antibodies Targeting Toxic Forms of Alpha-Synuclein February 15, 2019 ProMIS Neurosciences has identified several antibody candidates that specifically target the toxic forms of alpha-synuclein, a key component of Lewy bodies that underlie the development of Parkinson’s disease. In vitro (in the lab) studies have shown that ProMIS’s antibody candidates for Parkinson’s disease have a high specificity for toxic forms of alpha-synuclein without binding to non-toxic essential forms of the protein. Moreover, these antibody candidates prevent…
• Emerald Health Pharmaceuticals Appoints Lisa Sanford as Chief Financial Officer - GlobeNewswire March 12, 2019 Emerald Health Pharmaceuticals Appoints Lisa Sanford as Chief Financial Officer  GlobeNewswireSAN DIEGO, CA, March 12, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based ...
• ProMIS Neurosciences Appoints Renowned Parkinson’s Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board - Yahoo Finance June 19, 2019 ProMIS Neurosciences Appoints Renowned Parkinson’s Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board  Yahoo FinanceProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic ...
• Annovis Appoints Jeffrey McGroarty Chief Financial Officer - GlobeNewswire July 9, 2019 Annovis Appoints Jeffrey McGroarty Chief Financial Officer  GlobeNewswireBERWYN, Pa., July 09, 2019 (GLOBE NEWSWIRE) -- Annovis Bio, Inc., a biopharmaceutical company developing novel therapies for the treatment of ...
• ACADIA Pharmaceuticals Appoints Ponni Subbiah, MD, MPH, as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer - BioSpace November 4, 2019 ACADIA Pharmaceuticals Appoints Ponni Subbiah, MD, MPH, as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer  BioSpace
• Aptinyx Appoints Andy Kidd, M.D., President and Chief Operating Officer - Business Wire December 16, 2020 Aptinyx Appoints Andy Kidd, M.D., President and Chief Operating Officer  Business Wire
• Global Kinetics appoints Thomas Ulmer as Chief Financial Officer - GlobeNewswire December 22, 2020 Global Kinetics appoints Thomas Ulmer as Chief Financial Officer  GlobeNewswire